Data gathered: December 21
Alternative Data for United Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 45 | Sign up | Sign up | Sign up |
| Sentiment | 81 | Sign up | Sign up | Sign up |
| Webpage traffic | 19,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 75 | Sign up | Sign up | Sign up |
| Patents | 93 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 237 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,233 | Sign up | Sign up | Sign up |
| Instagram Followers | 73 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,164 | Sign up | Sign up | Sign up |
| Twitter Followers | 196 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 84 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,224 | Sign up | Sign up | Sign up |
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
| Price | $359.58 |
| Target Price | Sign up |
| Volume | 732,990 |
| Market Cap | $16.1B |
| Year Range | $231.78 - $410 |
| Dividend Yield | 0% |
| PE Ratio | 15.82 |
| Analyst Rating | 73% buy |
| Industry | Biotechnology |
In the news
United Therapeutics Announces Successful World's First UKidney TransplantDecember 17 - Finnhub |
|
 |
United Therapeutics President Michael Benkowitz sells $3.7M in sharesDecember 17 - Thefly.com |
 |
United Therapeutics Announces Successful World’s First UKidney TransplantDecember 16 - Yahoo |
 |
United Therapeutics management to meet with OppenheimerDecember 11 - Thefly.com |
 |
Hilltop Holdings Inc. Purchases Shares of 582 United Therapeutics Co. (NASDAQ:UTHR)December 9 - ETF Daily News |
|
United Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 7,700 SharesDecember 9 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 749M | 302M | 666M | 309M | 0 | 6.390 |
| Q2 '24 | 715M | 255M | 637M | 278M | 0 | 5.850 |
| Q1 '24 | 663M | 217M | 605M | 307M | 0 | 6.170 |
| Q4 '23 | 600M | 202M | 544M | 217M | 0 | 4.360 |
| Q3 '23 | 594M | 198M | 539M | 268M | 0 | 5.380 |
Insider Transactions View All
| SULLIVAN LOUIS W filed to sell 5,051 shares at $382.2. December 19 '24 |
| SULLIVAN LOUIS W filed to sell 17,680 shares at $379.3. December 19 '24 |
| SULLIVAN LOUIS W filed to sell 6,895 shares at $377.5. December 19 '24 |
| SULLIVAN LOUIS W filed to sell 17,880 shares at $374.5. December 19 '24 |
| SULLIVAN LOUIS W filed to sell 29,539 shares at $367. December 19 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul Republican |
Jun 22, 23 | Sell | $100K - $250K |
| Michael McCaul Republican |
Jun 22, 23 | Sell | $15K - $50K |
Read more about United Therapeutics (UTHR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of United Therapeutics?
The Market Cap of United Therapeutics is $16.1B.
What is United Therapeutics' PE Ratio?
As of today, United Therapeutics' PE (Price to Earnings) ratio is 15.82.
What is the current stock price of United Therapeutics?
Currently, the price of one share of United Therapeutics stock is $359.58.
How can I analyze the UTHR stock price chart for investment decisions?
The UTHR stock price chart above provides a comprehensive visual representation of United Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling United Therapeutics shares. Our platform offers an up-to-date UTHR stock price chart, along with technical data analysis and alternative data insights.
Does UTHR offer dividends to its shareholders?
As of our latest update, United Therapeutics (UTHR) does not offer dividends to its shareholders. Investors interested in United Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of United Therapeutics?
Some of the similar stocks of United Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.